Viatris Reports Stable Q3 2026 Results with Enhanced Profitability – Raises Full‑Year Guidance as Pacira BioSciences Acquisition Nears Completion

Viatris Inc. (NASDAQ: VTRS) reported its financial results for the third quarter of 2026, delivering stable revenues alongside enhanced profitability. The company simultaneously raised its full‑year guidance and announced it is nearing the completion of its acquisition of Pacira BioSciences, the non‑opioid pain management company being purchased for USD 36.50 per share in cash.

Financial Highlights

Core Products – Lipitor Leads the Portfolio

• Lipitor (atorvastatin): Generated USD 452 million in sales (+14.1% YoY), remaining the company’s largest single product.
• Zoloft: USD 78.8 million (+18%).
• Xalabrands: USD 43.9 million (+13.7%).
• Norvasc: USD 190 million (+5.8%).
• Creon: USD 98.1 million (+5.4%).
• Segment Dynamics: Branded growth (+1%) offset the −3% decline in generics, stabilizing the overall top line.

Pipeline & Acquisition Milestones

China Market – A Growth Engine

• Q3 Outperformance: Greater China revenues of USD 703 million rose 14% YoY (10% CC), outperforming the company’s overall growth rate and standing out as one of its top‑performing global markets.
• Nine‑Month Momentum: Cumulative Greater China revenues reached USD 2.1 billion, a 19% increase YoY (15% CC).
• Management Commentary: The financial report noted that brand growth “reflected continued strong performance in China and Emerging Markets.”

Market Impact & Outlook

• Guidance Raise: Lifting the FY 2026 revenue midpoint to USD 14.8 billion signals management confidence in branded portfolio momentum and emerging‑market growth.
• Portfolio Transformation: Closing the USD 1.65 billion Pacira deal adds a non‑opioid pain franchise, diversifying revenue beyond legacy branded and generics segments.
• Branded‑Led Mix Shift: With generics eroding (−3%) and branded products growing, Viatris’ mix is shifting toward higher‑value branded assets – including newly approved products such as RYZUMVI and WAKIX.
• China as Strategic Anchor: Double‑digit Greater China growth (+19% for nine months) positions the region as a key engine offsetting mature‑market pressure.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Viatris’ full‑year 2026 guidance, the closing of the Pacira BioSciences acquisition, product launches, and growth in Greater China and Emerging Markets. Actual results may differ due to risks including antitrust and regulatory review of the acquisition, pricing and reimbursement pressure, generic competition, currency fluctuations, and market adoption of newly approved products.-Fineline Info & Tech